Bausch + Lomb has acquired an exclusive license for a novel myopia control contact lens developed by a Sydney ophthalmic research institute, just days after signing another deal to commercialise an investigational microdose formulation of atropine. Read more
Australian of the Year and ophthalmologist Dr James Muecke has endorsed a new campaign aimed at motivating Australians in their 50s to have a macula check after it was revealed most in this age group are unable to identify macular disease risk factors. Read more
ASX-listed AFT Pharmaceuticals has expanded its therapeutics range with a new dry eye therapy containing Omega-3. Read more
A proposed merger between two pharmaceutical companies that compete in the glaucoma treatment markets has been given the green light – with one major stipulation. Read more
Australian researchers are using genetic testing to identify as many people as possible with inherited retinal disease (IRD), in preparation for an influx of life-changing gene and stem cell therapies expected over the next decade. Read more
For 40 years laser therapy has been the standard treatment for proliferative diabetic retinopathy (PDR), but now Australian ophthalmologists have a new option following regulatory approval of an existing drug. Read more
A US company that has incorporated dark adaptometry into a new wearable headset for age-related macular degeneration (AMD) is on the cusp of introducing the AI-guided technology to the Australian ophthalmic market. Read more
Adelaide ophthalmic device manufacturer Nova Eye Medical is developing a next generation iTrack glaucoma surgical system to reduce operating times. It is also progressing towards a pivotal US study for its 2RT laser therapy for intermediate AMD that could fulfil a distinct gap in a multi-billion-dollar market. Read more
In a historical development for the eye health sector, the Therapeutics Goods Administration (TGA) has approved the country’s first true gene therapy, indicated for a rare form of inherited retinal disease (IRD). Read more
In the final instalment of Insight’s five-part dry eye series, optometrist Ms Marilyn Stern reveals how low overheads and no refraction equipment set Perth’s first dedicated dry eye clinic apart. So too does its patient demographic, with several teens counted among them. Read more